In Vivo Transfection Reagent (LIPID-based)

In Vivo Transfection Reagent (POLYMER-based)

LIPID-based In Vivo Transfection Reagent

Catalog # 5010 - 0.5 mL (10 injections) $ 405.00 Catalog # 5011 - 1.5 mL (30 injections) $ 895.00 siRNA and plasmid DNA in vivo delivery reagent Modes of administration: Systemic intravenous (i.v.) injection Direct intratumoral (i.t.) injection Intraperitoneal (i.p.) injection Altogen's In Vivo Transfection Reagent Cationic lipid liposome-based reagent Lipid conjugated complexes are stable in serum for 16h Efficient delivery to the liver, pancreas, kidney, and certain tumor types via systemic administration Efficient siRNA and plasmid DNA delivery via direct subcutaneous tumor injection (various tumor types) Minimal toxicity Functionally tested in mice Applicable for plasmid DNA/siRNA co-injection Transfection protocols are provided with the purchase of the reagent Developed and manufactured by Altogen Biosystems

DATA

Figure 1. Systemic administration (i.v.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 2. Intratumoral administration (i.t.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

 

POLYMER-based In Vivo Transfection Reagent

Catalog # 5020 - 0.5 mL (10 injections) $ 425.00 Catalog # 5021 - 1.5 mL (30 injections) $ 935.00 siRNA and plasmid DNA in vivo delivery reagent Modes of administration: Systemic intravenous (i.v.) injection Direct intratumoral (i.t.) injection Altogen's In Vivo Transfection Reagent Biodegradable polymer-based In Vivo reagent No detectable inflammatory response Efficient delivery to the lung, liver, kidney, and spleen via systemic administration Efficient siRNA and plasmid DNA delivery via direct subcutaneous tumor injection (multiple tumor types) Functionally tested in mice Applicable for plasmid DNA/siRNA co-injection Transfection protocols are provided with the purchase of the reagent Developed and manufactured by Altogen Biosystems

DATA

Figure 3. Systemic administration (i.v.) of Polymer-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 4. Intratumoral administration (i.t.) of Polymer-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

siRNA Transfection

Gene silencing by RNA Interference (RNAi) is a powerful research tool for studying gene function in mammalian cells. RNAi is a biological phenomenon by which double stranded RNA (dsRNA) specifically reduces gene expression of its corresponding gene. Potent inhibition of specific gene expression is experimentally achieved by the transfection of small interfering RNA (siRNA), which binds RISC complex and cause degradation of target complementary mRNA molecules in the cell. Therefore, successful, potent RNAi experimentation is dependent upon the highly efficient delivery of the siRNA into cells by transfection of stable and functional siRNA molecules. Most DNA transfection reagents are incompatible with siRNA, sensitive to serum, or are capable of inducing cytotoxicity, which negatively affects gene expression studies. Transfection Reagents have been developed and optimized specifically for use with siRNA transfection and allow transfection in the presence of serum without lowering transfection efficiency or reducing cell viability. Ready-to-run transfection protocols eliminate the need for extensive siRNA optimization experiments. Altogen Biosystems kits are also compatible for transfection of microRNA (miRNA) molecules.

Product Review

Article by Dr.Lakshmanan "A549 Transfection Reagent From Altogen Biosystems": Link

Altogen Biosystems

Altogen Biosystems is a life sciences company dedicated to the development, marketing and manufacture of cell type specific transfection reagents. Efficient delivery of DNA, RNA, siRNA, and microRNA enabled by advanced formulation of reagents and peculiar design of protocols. Altogen Biosystems offers a complete transfection system for a broad range of cell lines. All in vitro and in vivo reagents are functionally tested to be highly reproducible, serum compatible, induce low toxicity, and can be used for co-transfection experiments, and high throughput applications.